JANESVILLE, Wis., Aug. 9, 2019 – SHINE Medical Technologies LLC today announced it has received a $15-million award from the Department of Energy’s National Nuclear Security Administration (DOE/NNSA). The award was made by the agency as part of its effort to establish a reliable, U.S.-produced supply of molybdenum-99 (Mo-99), the most commonly used medical isotope, without the use of highly enriched uranium.
Many companies developing artificial intelligence software for healthcare are trying to improve doctors’ ability to diagnose disease. Fewer emerging healthcare AI businesses are focused on what happens after a diagnosis, aiming to figure out how treatments are working.
July 22nd, 2019 – JANESVILLE, WI – SHINE Medical Technologies LLC today announced that the company has filed an application with the U.S. Nuclear Regulatory Commission to produce medical isotopes, including molybdenum-99 (Mo-99), iodine-131 and xenon-133, at its production facility in Janesville, WI.
MINNEAPOLIS–(BUSINESS WIRE)–POPS! Diabetes Care—a revolutionary diabetes care management company—is excited to announce that it has closed an oversubscribed Series A funding round of $6 million USD due to strong investor demand.
ANESVILLE, Wis., June 19, 2019 /PRNewswire/ — Phoenix, LLC, a Madison, WI nuclear technology company, and SHINE Medical Technologies, a Janesville, WI medical isotope production company, today announced completion of a 132-hour test of the high-flux Phoenix neutron generator that will drive SHINE’s medical isotope production system. This is a vital milestone in proving out the performance and reliability of Phoenix’s neutron generator technology and SHINE’s medical isotope production process.
Recent Comments